Vaginal Health
Conditions
Brief summary
A randomized, placebo-controlled trial to assess the Pharmacokinetics and Pharmacodynamics of a novel synbiotic dietary supplement for vaginal health.
Detailed description
This is a randomized, double-blind, placebo-controlled, decentralized clinical trial that will enroll approximately 200 healthy women aged 21-60 years old who meet all eligibility criteria. Eligible participants will be stratified based on key factors. Following stratification, participants will be randomized to one of the study arms (placebo or VV-01 product) using block randomization. Participants will have a 1:1 chance of receiving the active study product or the placebo. Participants will receive study kits containing the study product, administration supplies, biomarker self-collection materials, and comprehensive instructions for product use and sample collection. The duration of the study for each participant will be approximately 2 weeks following enrollment.
Interventions
DIETARY_SUPPLEMENTVaginal Health Placebo Control
Vaginal Health Placebo Control Participants will orally ingest Vaginal Health Placebo Control once daily as directed for a period of 2 weeks
DIETARY_SUPPLEMENTVaginal Health Active VV-01
Product 1 Participants will orally ingest Vaginal Health Active Product 1 once daily as directed for a period of 2 weeks.
Sponsors
Radicle Science
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Masking description
Double (Participant, Investigator): The investigator is blinded to the participants' assigned study products. Participants are blinded to the study product they received.
Intervention model description
Parallel Assignment. Participants will be sequentially randomized to one of two study groups, with an equal (1:1) chance of receiving the study product or placebo
Eligibility
Sex/Gender
FEMALE
Age
21 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
Participants must meet all the following criteria: * Healthy women with a vagina 21 - 60 years old at the time of electronic consent * Sex assigned female at birth * Eligible menstrual status: * Pre-menopausal is defined as women in their childbearing years who must have a regular menstrual cycle (consistently average cycle length of 21 to 35 days) Note: Women in their childbearing years who do not have a regular menstrual cycle due to a hormone-based intrauterine device are eligible * Peri-menopausal is defined as women who report irregular periods (differences in menstruation compared with their typical cycle in their 20s), with at least 1 period in the last 12 months AND report mild menopausal symptoms (e.g., vasomotor symptoms such as hot flashes, night sweats) * Post-menopausal is defined as women with an absence of menstrual cycle for the last 12 consecutive months or longer * Willing to ingest an oral capsule during the study and be blinded to product identity (active or placebo) * Willing to self-collect vaginal swabs and pH samples * Willing to abstain from the use of intravaginal products during the study period (e.g., vaginal suppositories, vaginal moisturizers including hyaluronic acid, boric acid suppositories, pH balancing wipes, douching, vaginal creams/gels), as well as lubrication and spermicides * Able to read and comprehend English and provide electronic informed consent * Resides in the United States
Exclusion criteria
* Active vaginal, pelvic, or urogenital infection (e.g., UTI, BV, yeast infection) * Chronic vulvar and vaginal conditions (e.g., vulvodynia, lichen sclerosis and lichen planus, desquamative inflammatory vaginitis) * Unexplained vaginal bleeding * Use of copper-based intrauterine devices * Note: Hormone-based intrauterine devices are permitted (e.g., Mirena®) * For peri-menopausal and post-menopausal individuals, use of estrogen-based vaginal cream/gel or suppositories * Women who have undergone surgical menopause (e.g., bilateral oophorectomy with or without hysterectomy) * Current or recent use (\< 3 months prior to enrollment) of antibiotics or antifungals, or anticipated use during study period (e.g., perioperative antibiotics for upcoming elective procedures) * Current or recent use (\<4 weeks prior to enrollment) of any other probiotic, prebiotic or synbiotic-containing products * Note: Individuals who undergo a washout of 4-weeks prior to enrollment and are willing to abstain from consuming such products during the study are permitted. Food-based probiotics, prebiotics, and synbiotics are permitted (e.g., kimchi, yoghurt, kefir, kombucha) * Pregnant, breastfeeding, or actively trying to conceive during the study period. * Allergy to any ingredients in the investigational or placebo product. * Receiving chronic oral steroid therapy (excluding those for skin, eyes, nose, or inhaled) or have received such treatment within 4 weeks of enrollment * Surgery, immunotherapy, chemotherapy, radiation, or biological cancer therapy within 4 weeks of enrollment and/or planned during the next 2 weeks * Diagnosed and active serious medical condition requiring current treatment (e.g., cancer; autoimmune diseases \[lupus, rheumatoid arthritis, Crohn's disease\]; serious cardiac, liver, endocrine (insulin-dependent diabetes and/or on SGLT2 inhibitors such as Jardiance®/Empagliflozin, Farxiga®/Dapagliflozin) or kidney disease; psychiatric conditions / substance use disorders; chronic infections \[HIV, Hepatitis B/C\], any condition which in the investigator's opinion may jeopardize the individual's safety or interfere with the ability to comply with the study * Participation in another clinical trial within 90 days of screening * International travel during the study period
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Colonization of VV-01 probiotic strains in the vagina | Baseline to Day 14 | Colonization of VV-01 probiotic strains in the vagina assessed using strain-specific qPCR from vaginal swabs |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Vaginal microbial ecosystem structure | Baseline to Day 14 | Structure of the vaginal microbiome assessed by metagenomic sequencing of vaginal swabs |
| Biogenic amines production capability in the vaginal microbiome | Baseline to Day 14 | Biogenic amines production capability assessed by metagenomic sequencing (functional genomics) of vaginal swabs |
| Safety and tolerability | Baseline to Day 14 | Safety and tolerability assessed through observation of serious adverse events |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORSusan Hewlings
Radicle Science
Outcome results
None listed